Provided by Tiger Trade Technology Pte. Ltd.

IDEAYA Biosciences

40.04
+0.37000.93%
Post-market: 40.840.8000+2.00%19:59 EDT
Volume:786.77K
Turnover:31.56M
Market Cap:3.85B
PE:-20.47
High:40.46
Open:39.73
Low:39.12
Close:39.67
52wk High:40.58
52wk Low:23.23
Shares:96.27M
Float Shares:94.37M
Volume Ratio:0.88
T/O Rate:0.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9561
EPS(LYR):-1.2849
ROE:-16.22%
ROA:-11.54%
PB:3.22
PE(LYR):-31.16

Loading ...

IDEAYA Biosciences: Operational Trial Delay but High Conviction Buy Ahead of Key Darovasertib Readout

TIPRANKS
·
Mar 23

IDEAYA forecasts OptimUM-02 trial database lock in April 2026

Reuters
·
Mar 22

IDEAYA Biosciences to host darovasertib OptimUM-02 topline results webcast and attend Bank of America health care conference

Reuters
·
Mar 22

IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance From Phase 2/3 Optimum-02 Trial

THOMSON REUTERS
·
Mar 22

IDEAYA Biosciences to present three posters at AACR Annual Meeting

Reuters
·
Mar 18

IDEAYA Biosciences (IDYA) Gets a Buy from Mizuho Securities

TIPRANKS
·
Mar 17

Analysts’ Top Healthcare Picks: IDEAYA Biosciences (IDYA), Lantheus (LNTH)

TIPRANKS
·
Mar 09

BRIEF-Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of IDE892

Reuters
·
Mar 09

IDEAYA Biosciences reports first patient enrolled in Phase 1 IDE892 trial for MTAP-deleted solid tumors

Reuters
·
Mar 09

IDEAYA Biosciences Inc - Targets Cdkn2a Development Candidate Nomination in H2 2026 and Ind in H1 2027

THOMSON REUTERS
·
Mar 09

IDEAYA Biosciences Announces First-Patient-in for Phase 1 Trial of Ide892, a Potential Best-in-Class Prmt5 Inhibitor for Mtap-Deleted Solid Tumors, and Provides Mtap and Cdkn2a Pipeline Update

THOMSON REUTERS
·
Mar 09

IDEAYA Biosciences Inc - Ide892 to Be Combined With Ide397 in Phase 1 Trial in Mid-2026

THOMSON REUTERS
·
Mar 09

IDEAYA Biosciences Director Jeffrey Stein Acquires Common Shares

Reuters
·
Mar 03

BRIEF-Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Feb 27

IDEAYA Biosciences Grants 346,200 Inducement Stock Options to New Hires

Reuters
·
Feb 27

BRIEF-Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of Ide034, A Potential First-In-Class B7h3/Ptk7 Bispecific Top1 Adc

Reuters
·
Feb 25

IDEAYA Biosciences Enrolls First Patient in Phase 1 IDE034 Trial

Reuters
·
Feb 25

IDEAYA Biosciences Inc - First Patient Dosing With Ide034 Triggers $5 Mln Payment to Biocytogen

THOMSON REUTERS
·
Feb 25

IDEAYA Biosciences Announces First-Patient-in for Phase 1 Trial of Ide034, a Potential First-in-Class B7h3/Ptk7 Bispecific Top1 ADC

THOMSON REUTERS
·
Feb 25